Recent progress in cell therapy for basal ganglia disorders with emphasis on menstrual blood transplantation in stroke. Neurosci Biobehav Rev

Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., Tampa, FL, USA.
Neuroscience & Biobehavioral Reviews (Impact Factor: 8.8). 05/2011; 36(1):177-90. DOI: 10.1016/j.neubiorev.2011.05.010
Source: PubMed


Cerebrovascular diseases are the third leading cause of death and the primary cause of long-term disability in the United States. The only approved therapy for stroke is tPA, strongly limited by the short therapeutic window and hemorrhagic complications, therefore excluding most patients from its benefits. Parkinson's and Huntington's disease are the other two most studied basal ganglia diseases and, as stroke, have very limited treatment options. Inflammation is a key feature in central nervous system disorders and it plays a dual role, either improving injury in early phases or impairing neural survival at later stages. Stem cells can be opportunely used to modulate inflammation, abrogate cell death and, therefore, preserve neural function. We here discuss the role of stem cells as restorative treatments for basal ganglia disorders, including Parkinson's disease, Huntington's disease and stroke, with special emphasis to the recently investigated menstrual blood stem cells. We highlight the availability, proliferative capacity, pluripotentiality and angiogenic features of these cells and explore their present and future experimental and clinical applications.

28 Reads
  • Source
    • "Furthermore several studies demonstrated the feasibility of stem cell-based therapy for the restoration of lost brain function[131420] and improvement of the clinical outcome in stroke patients.[10282930] Several experimental and clinical researches have introduced different types of stem cell for transplantation in stroke.[1114151620222728293031323334353637] In recent years, different experimental and clinical cell transplantation studies have been started in Iran, as a leading country in the Middle East[38] for central nervous system (CNS) disorders including; spinal cord injury (SCI)[21394041] and stroke.[42] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nowadays, scientific findings in the field of regeneration of nervous system have revealed the possibility of stem cell based therapies for damaged brain tissue related disorders like stroke. Furthermore, to achieve desirable outcomes from cellular therapies, one needs to monitor the migration, engraftment, viability, and also functional fate of transplanted stem cells. Magnetic resonance imaging is an extremely versatile technique for this purpose, which has been broadly used to study stroke and assessment of therapeutic role of stem cells. In this review we searched in PubMed search engine by using following keywords; "Stem Cells", "Cell Tracking", "Stroke", "Stem Cell Transplantation", "Nanoparticles", and "Magnetic Resonance Imaging" as entry terms and based on the mentioned key words, the search period was set from 1976 to 2012. The main purpose of this article is describing various advantages of molecular and magnetic resonance imaging of stem cells, with focus on translation of stem cell research to clinical research.
    Full-text · Article · May 2014 · Journal of research in medical sciences
  • Source
    • "Non-immunogenic nature and lack of tumor formation capability, as shown in our study, are among other outstanding advantages that make MenSCs a suitable candidate for cell therapy. While current reports of animal studies on MenSCs-based therapy for some diseases such as cardiac [38], muscular [39] and nervous system disorders [40], [41] hold promise for cell-based therapy using these stem cells, there is very limited information about MenSCs potential to generate hepatocytes [8], [16], particularly compared with other known stem cells such as BMSCs. In this study, some protocol-dependent differences were beheld between hepatogenic differentiation potential of MenSCs and BMSCs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Menstrual blood has been introduced as an easily accessible and refreshing stem cell source with no ethical consideration. Although recent works have shown that menstrual blood stem cells (MenSCs) possess multi lineage differentiation capacity, their efficiency of hepatic differentiation in comparison to other stem cell resources has not been addressed so far. The aim of this study was to investigate hepatic differentiation capacity of MenSCs compared to bone marrow-derived stem cells (BMSCs) under protocols developed by different concentrations of hepatocyte growth factor (HGF) and oncostatin M (OSM) in combination with other components in serum supplemented or serum-free culture media. Such comparison was made after assessment of immunophenotye, trans-differentiation potential, immunogenicity and tumorigeicity of these cell types. The differential expression of mature hepatocyte markers such as albumin (ALB), cytokeratin 18 (CK-18), tyrosine aminotransferase and cholesterol 7 alpha-hydroxylase activities (CYP7A1) at both mRNA and protein levels in differentiating MenSCs was significantly higher in upper concentration of HGF and OSM (P1) compared to lower concentration of these factors (P2). Moreover, omission of serum during differentiation process (P3) caused typical improvement in functions assigned to hepatocytes in differentiated MenSCs. While up-regulation level of ALB and CYP7A1 was higher in differentiated MenSCs compared to driven BMSCs, expression level of CK-18, detected level of produced ALB and glycogen accumulation were lower or not significantly different. Therefore, based on the overall comparable hepatic differentiation ability of MenSCs with BMSCs, and also accessibility, refreshing nature and lack of ethical issues of MenSCs, these cells could be suggested as an apt and safe alternative to BMSCs for future stem cell therapy of chronic liver diseases.
    Full-text · Article · Feb 2014 · PLoS ONE
  • Source
    • "Both intracerebral and intravenous transplantation of menstrual blood-derived cells into stroke model rats improved host cell survival and behavioral functions [127]. These cells have also been implemented for in vivo surgical MCAO rat studies without immunosuppression [127,128,129]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stem cell-based therapies for stroke have expanded substantially over the last decade. The diversity of embryonic and adult tissue sources provides researchers with the ability to harvest an ample supply of stem cells. However, the optimal conditions of stem cell use are still being determined. Along this line of the need for optimization studies, we discuss studies that demonstrate effective dose, timing, and route of stem cells. We recognize that stem cell derivations also provide uniquely individual difficulties and limitations in their therapeutic applications. This review will outline the current knowledge, including benefits and challenges, of the many current sources of stem cells for stroke therapy.
    Full-text · Article · Jul 2013
Show more